Magenta Therapeutics
CD117 antibody conditioning regimen for stem cell transplantation
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Founded
- 2015
- Latest Form D
- $52.3M, Apr 2018
- Total capital
- $117M
- Federal grants
- $514K
- 1 award · 2020
- At sector median 1 award
- Private capital raised
- $116M
- 3 Form D · last Apr 2018
- 103 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 13
- 27 pending · first 2018
- Rank in peer group#131 of 1449
Capital timeline
Latest events
- Federal grantHealth and Human S · U19 · Nongenotoxic conditioning for HIV cure transplantation approaches$514K
- Private capital raisedForm D · SEC · 3rd filing$52.3M
- Private capital raisedForm D · SEC · 2nd filing$46M
- Private capital raisedForm D · SEC · 1st filing$17.7M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#131 · top 9%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alexis BorisyDirectorNamed in SEC Form D filings
- Amy RonnebergDirectorNamed in SEC Form D filings
- Bastiano SannaExecutive OfficerNamed in SEC Form D filings
- Blake ByersDirectorNamed in SEC Form D filings
- Bruce BoothDirectorNamed in SEC Form D filings
- David ScaddenDirectorNamed in SEC Form D filings
Show all 12 people
- Jason GardnerExecutive Officer, DirectorNamed in SEC Form D filings
- Jeffrey AlbersDirectorNamed in SEC Form D filings
- John DavisExecutive OfficerNamed in SEC Form D filings
- Michael BonneyDirectorNamed in SEC Form D filings
- Thomas DanielDirectorNamed in SEC Form D filings
- Zoran ZdraveskiExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 13 granted of 40- PendingCompositions And Methods For The Depletion Of CellsUSPTOApplication 18501451
- PendingFc Silenced Antibody Drug Conjugates (adcs) And Uses ThereofUSPTOApplication 18156305
- PendingCompositions And Methods For Treating Hematological MalignanciesUSPTOApplication 18110093
Show all 40 patent records
- Compositions And Methods For The Depletion Of CellsJun 27, 2024 · Application 18501451Pending
- Fc Silenced Antibody Drug Conjugates (adcs) And Uses ThereofMar 7, 2024 · Application 18156305Pending
- Compositions And Methods For Treating Hematological MalignanciesDec 28, 2023 · Application 18110093Pending
- Dosing Regimens For The Mobilization Of Hematopoietic Stem CellsApr 27, 2023 · Application 17743097Pending
- Novel Linkers For Antibody-drug Conjugates And Related Compounds, Compositions, And Methods Of UseApr 6, 2023 · Application 17545562Pending
- ANTI-CD117 Antibodies And ConjugatesFeb 7, 2023 · US 11,572,411Granted
- Dosing Regimens For The Mobilization Of Hematopoietic Stem And Progenitor CellsDec 22, 2022 · Application 17773422Pending
- Conditioning Methods For Gene TherapyJun 9, 2022 · Application 17507456Pending
- Dosing Regimens For The Mobilization Of Hematopoietic Stem And Progenitor CellsMar 31, 2022 · Application 17314581Pending
- Use Of An ANTI-CD45 Antibody Drug Conjugate (adc) In Cell TherapyMar 3, 2022 · Application 17368815Pending
- Dosing Regimens For The Mobilization Of Hematopoietic Stem And Progenitor CellsMar 1, 2022 · US 11,260,079Granted
- Novel Linkers For Antibody-drug Conjugates And Related Compounds, Compositions, And Methods Of UseJan 25, 2022 · US 11,229,711Granted
- Therapeutic Methods Using Antibody Drug Conjugates (adcs)Sep 16, 2021 · Application 17111816Pending
- Use Of An ANTI-CD2 Antibody Drug Conjugate (adc) In Allogeneic Cell TherapyAug 26, 2021 · Application 17155721Pending
- Aryl Hydrocarbon Receptor Antagonists And Uses ThereofJun 17, 2021 · Application 17126524Pending
- Compositions And Methods For The Depletion Of CD134+ CellsApr 8, 2021 · Application 16932319Pending
- ANTI-CD252 Antibodies, Conjugates, And Methods Of UseApr 1, 2021 · Application 17013172Pending
- Aryl Hydrocarbon Receptor Antagonists And Uses ThereofFeb 16, 2021 · US 10,919,900Granted
- Compositions And Methods For The Depletion Of CD117+ CellsJan 26, 2021 · US 10,899,843Granted
- Compositions And Methods For The Depletion Of CD117+ CellsJan 5, 2021 · US 10,882,915Granted
- Amatoxin Antibody-drug Conjugates And Uses ThereofDec 31, 2020 · Application 16858509Pending
- Antibody-drug Conjugates And Related Compounds, Compositions And MethodsDec 17, 2020 · Application 16728045Pending
- Fc Silenced Antibody Drug Conjugates (adcs) And Uses ThereofDec 3, 2020 · Application 16858481Pending
- Compositions And Methods For The Depletion Of CellsDec 3, 2020 · Application 16853619Pending
- Modified Antibodies And Related Compounds, Compositions, And Methods Of UseSep 22, 2020 · US 10,781,259Granted
- Compositions And Methods For The Depletion Of CD5+ CellsSep 3, 2020 · Application 16851082Pending
- Fc Silenced Antibodies And Antibody Drug Conjugates (adcs)Aug 13, 2020 · Application 16863948Pending
- Methods For The Depletion Of CellsApr 21, 2020 · US 10,624,973Granted
- Compositions And Methods For The Depletion Of CD137+ CellsMar 3, 2020 · US 10,576,161Granted
- Compositions And Methods For Hematopoietic Stem And Progenitor Cell Transplant TherapyNov 14, 2019 · Application 16177254Pending
- Dosing Regimens For The Mobilization Of Hematopoietic Stem And Progenitor CellsNov 7, 2019 · Application 16212497Pending
- Compositions And Methods For The Depletion Of CellsOct 31, 2019 · Application 16310738Pending
- Aryl Hydrocarbon Receptor Antagonists And Uses ThereofOct 29, 2019 · US 10,457,683Granted
- Compositions And Methods For The Expansion Of Hematopoietic Stem And Progenitor CellsOct 17, 2019 · Application 16177252Pending
- Compositions And Methods For The Depletion Of CD137+ CellsOct 8, 2019 · US 10,434,185Granted
- Aryl Hydrocarbon Receptor Antagonists And Uses ThereofJul 16, 2019 · US 10,351,572Granted
- Dosing Regimens for the Mobilization of Hematopoietic Stem CellsJun 6, 2019 · Application 16101676Pending
- Compositions And Methods For The Depletion Of CD117+ CellsMay 9, 2019 · Application 16158164Pending
- Dosing Regimens For The Mobilization Of Hematopoietic Stem CellsAug 28, 2018 · US 10,058,573Granted
- Antibody-drug Conjugates, Compositions And Methods Of UseMay 31, 2018 · Application 15642225Pending
Related companies, and why
- Secura Bio Holdings, Inc.Similar federal contract value in Biotech · null in contracts
- CELLULAR DYNAMICS INTERNATIONAL, INC.Similar federal contract value in Biotech · null in contracts
- Delix TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Vor BiopharmaSimilar federal contract value in Biotech · null in contracts
- Sail BiomedicinesSimilar federal contract value in Biotech · null in contracts
- REMD BIOTHERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .